Sanofi (NASDAQ:SNY) Bolsa

Sanofi

NYSE

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Equities

Large Cap

News

Buybacks

Movers

General

LRLCF

LRLCY

Sanofi adquiere 29,6 millones de acciones a L&#39;Oréal en una transacción de 3000M€. Descubre el impacto en la empresa y sus accionistas.

Sanofi recompra 2,3% de sus acciones a L&#39;Oréal por 3000M€

Health Care

Markets

IDNA

MRNA

NVAX

El brote de H5N9, la separación de la OMS y las audiencias de Kennedy generan incertidumbre en salud pública y mercados.

Acciones de Moderna (MRNA) y Pfizer (PFE) reaccionan al brote de H5N9 y la separación de los CDC de la OMS

Biotech

Descubre los prometedores resultados del estudio de fase 3 IRAKLIA de Sanofi sobre Sarclisa SC en mieloma múltiple.

Sanofi publica resultados prometedores del estudio de fase 3 IRAKLIA con Sarclisa

Sanofi SA

Synthetify

SUNNYLIFE GLOBAL INC by Sunnylife Global, Inc.

Sunnylife Global Inc

Synergy CHC Corp

VITAL ENERGY INC (CDA) by Vital Energy, Inc.

Vital Energy Inc

SANY HEAVY EQUIP INTL HLD by Sany Heavy Equipment International Holdings Co.

Sany Heavy Equipment International Holdings Co Ltd

Sanofi NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) has been flexing its biotech muscles, and investors are taking notice. The stock is firmly in bullish territory, recently forming <a href="https://www.benzinga.com/topic/golden-cross">a Golden Cross</a>, a classic technical signal that often precedes further gains.
With momentum traders piling in and Sanofi's latest Dupixent breakthrough adding serious fuel to the rally, the stock is in the spotlight.
<h2 class="wp-block-heading">Sanofi Stock Chart Screams Bullish</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="618" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12085643/Screenshot-2025-03-12-at-4.37.48-PM.png" alt="" class="wp-image-820812" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12085643/Screenshot-2025-03-12-at-4.37.48-PM.png 618w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12085643/Screenshot-2025-03-12-at-4.37.48-PM-300x236.png 300w" sizes="(max-width: 618px) 100vw, 618px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Sanofi stock is up 21.89% year-to-date. Its eight-day, 20-day, 50-day and even 200-day moving averages all point higher. 
The stock also completed a Golden Cross, where the 50-day moving average crosses above the 200-day moving average, a signal that typically indicates a long-term uptrend.
The MACD (moving average convergence/divergence) indicator sits at 1.77, another bullish signal, while an RSI (relative strength index) of 69.91 puts it just on the edge of overbought territory &#8211; suggesting the rally might still have room to run.
Read Also: <a href="https://www.benzinga.com//node/44245496">Top 3 Health Care Stocks That May Keep You Up At Night In Q1</a>
<h2 class="wp-block-heading">Dupixent's Big Moment</h2>
The real game-changer? Sanofi's blockbuster drug <a href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-03-08-18-00-00-3039375">Dupixent just posted</a> strong Phase 2/3 trial results for treating bullous pemphigoid (BP).
The drug improves disease remission and reduces severity. It also cut the need for corticosteroids—potentially setting the stage for a first-of-its-kind treatment.
With regulatory submissions under review in the US and EU, the FDA has granted priority review, with a decision expected by June 2025. 
If approved, Dupixent could tap into yet another lucrative market, further cementing its blockbuster status.
With a Golden Cross reinforcing its bullish momentum and a major FDA decision looming, investors are watching closely—because this rally might just be getting started.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com//node/44252770">Merck Injects $1 Billion To Expand Vaccine Production In US</a></li>
</ul>
Image: Shutterstock

Long Ideas

Technicals

Trading Ideas

Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?

On Tuesday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) opened a new $1 billion, 225,000-square-foot facility for vaccine manufacturing at its Durham, <a target="_blank" href="https://www.benzinga.com/news/large-cap" rel="noreferrer noopener">North Carolina, site</a>.
This expansion is a crucial component of the more than $12 billion Merck has invested in the U.S. since 2018. It&#8217;s focused on expanding domestic manufacturing and research and development capabilities. The company also aims to create new jobs in the U.S., with another $8-billion capital investment <a href="https://www.benzinga.com/pressreleases/25/03/b44242543/merck-unveils-new-facility-to-increase-vaccine-production-capacity" target="_blank" rel="noreferrer noopener">by 2028</a>.
Also Read: <a href="https://www.benzinga.com/25/03/44101319/pfizer-mulls-us-manufacturing-shift-amid-looming-tariff-threats-will-the-trump-administration-co-invest-asks-analyst" target="_blank" rel="noreferrer noopener">Pfizer CEO Says Company May Shift Overseas Manufacturing To US Amid Looming Tariff Threats</a>
During the fourth quarter, Merck reported a decline of 17% in sales of Gardasil to $1.55 billion. Gardasil is a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S. 
The decline is primarily due to lower demand in China, partially offset by higher demand in most international regions, <a href="https://www.benzinga.com/25/02/43461426/mercks-gardasil-vaccine-slowdown-in-china-bites-again-stock-falls-on-lower-than-expected-2025-outlook" target="_blank" rel="noreferrer noopener">particularly in Japan</a>.
Merck expects fiscal year 2025 sales of $64.1 billion-$65.6 billion versus a consensus of $67.31 billion,&nbsp;including a negative impact of foreign exchange of approximately 2% at mid-January 2025 exchange rates.
The sales range reflects a decision to temporarily pause Gardasil/Gardasil 9 shipments into China beginning February 2025 through at least mid-year.
In February, at a press conference in&nbsp;Washington, D.C.,&nbsp;Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" rel="noreferrer noopener">manufacturing sites in&nbsp;the U.S</a>.
The company is currently negotiating with several states. The company's previous domestic capital expansion commitments from 2020 to&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42370795/investments-in-eli-lillys-production-capabilities-reaches-23-billion-with-additional-3-billion-expansion-at-us-facility" rel="noreferrer noopener">2024 totaled&nbsp;$23 billion</a>.
In January, the U.S. Food and Drug Administration (FDA) issued a warning letter to Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>). 
After an inspection conducted last year, the agency flagged major concerns about Genzyme's processes <a href="https://www.benzinga.com/general/biotech/25/01/43142442/sanofi-genzyme-facility-fda-quality-lapses">for producing active pharmaceutical ingredients</a>.
Price Action: Merck stock is down 1.53% at $93.78 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44246625/dicks-sporting-beats-q4-earnings-stock-falls-amid-soft-outlook" target="_blank" rel="noreferrer noopener">Dick&#8217;s Sporting Beats On Q4 Earnings, Stock Falls Amid Soft Outlook</a></li>
</ul>
Image: Courtesy of Merck

Merck Injects $1 Billion To Expand Vaccine Production In US

As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">2Seventy Bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>)</h3>
<ul>
<li>On March 10, 2seventy bio agreed to be acquired by Bristol Myers Squibb for $5.00 per share in 88% premium transaction valued at $286 million. &#8220;A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living with multiple myeloma and maximizing value for all stakeholders,&#8221; said Chip Baird, chief executive officer, 2seventy bio. &#8220;The strategic rationale for this acquisition is clear and today&#8217;s announcement represents the culmination of the journey for 2seventy bio." The company's stock gained around 20% over the past month and has a <a href="https://www.benzinga.com/quote/TSVT">52-week high of $5.99</a>.</li>
<li>RSI Value: 82.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TSVT Price Action: Shares of 2Seventy Bio gained 5.3% to close at $2.80 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)</h3>
<ul>
<li>On Feb. 14, the FDA approved Sanofi's Merilog as a biosimilar to Novo Nordisk A/S‘ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Novolog (insulin aspart) for improving glycemic control in adults and pediatric patients with diabetes mellitus.. The company's stock gained around 10% over the past month and <a href="https://www.benzinga.com/quote/SNY">has a 52-week high</a> of $60.12.</li>
<li>RSI Value: 77.4</li>
<li>SNY Price Action: Shares of Sanofi gained 0.2% to close at $59.35 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)</h3>
<ul>
<li>On Feb. 10, Vertex Pharmaceuticals posted better-than-expected quarterly sales. &#8220;2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year with the landmark JOURNAVX approval and launch for moderate-to-severe acute pain; the launch of our fifth CF medicine, ALYFTREK; the continuing global launch of CASGEVY; and multiple ongoing pivotal trials. We are excited to drive diversification of the revenue base, disease areas of focus, R&amp;D pipeline, and geographies to continue to deliver long-term value to both patients and shareholders,&#8221; said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. The company's stock gained around 10% over the past month and has a <a href="https://www.benzinga.com/quote/VRTX">52-week high </a>of $519.88.</li>
<li>RSI Value: 74</li>
<li>VRTX Price Action: Shares of Vertex Pharmaceuticals gained 2.4% to close at $500.01 on Monday. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44218016/top-3-financial-stocks-that-may-fall-off-a-cliff-in-march">Top 3 Financial Stocks That May Fall Off A Cliff In March</a></li>
</ul>

Short Ideas

Pre-Market Outlook

TSVT

VRTX

Top 3 Health Care Stocks That May Keep You Up At Night In Q1

On Saturday, Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Kyowa Kirin Co., Ltd. <a href="https://www.benzinga.com/general/biotech">announced new results</a> from the ongoing ROCKET Phase 3 trial program rocatinlimab in moderate to severe atopic dermatitis (AD).
The IGNITE study evaluated two dose strengths of rocatinlimab and met its co-primary endpoints and all key secondary<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44208802/amgen-and-kyowa-kirin-provide-top-line-results-from-rocatinlimab-phase-3-ignite-study-in-adults-wi" rel="noreferrer noopener"> endpoints versus placebo</a>.
<ul>
<li>At week 24, 42.3% of patients in the higher dose group achieved ≥75% reduction from baseline in Eczema Area and Severity Index score (EASI-75), a 29.5% difference vs. placebo, and 36.3% vs. 23.4% in the lower dose group.</li>
<li>In the higher dose group, 23.6% of patients achieved a validated Investigator&#8217;s Global Assessment for Atopic Dermatitis score of 0 (clear) or 1 (almost clear) with a ≥2-point reduction from baseline (vIGA-AD 0/1) at week 24, representing a 14.9% difference vs. placebo.</li>
<li>In the lower dose group, 19.1% of patients achieved this endpoint, a 10.3% difference vs. placebo.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44159237/amgen-challenges-novo-nordisk-and-eli-lilly-as-its-monthly-weight-loss-drug-maritide-enters-two-late-stage-trials" rel="noreferrer noopener">Amgen Challenges Novo Nordisk&#8217;s Ozempic And Eli Lilly&#8217;s Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials</a>
In addition, IGNITE met the endpoint of the revised Investigator&#8217;s Global (rIGA) Assessment score of 0/1 with a ≥2-point reduction from baseline.
<ul>
<li>At week 24, 22.7% of patients in the higher dose group achieved this endpoint, a 14.4% difference vs. placebo.</li>
<li>In the lower dose group, 16.3% of patients achieved this endpoint, an 8.0% difference vs. placebo.</li>
</ul>
The ROCKET program is also informed by the results of the SHUTTLE and VOYAGER studies.
<ul>
<li>The SHUTTLE study evaluated two dose strengths of rocatinlimab in combination with topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCI) in 746 adults using the same co-primary endpoints as IGNITE. The study met its co-primary and all key secondary endpoints.
<ul>
<li>For EASI-75, 52.3% of patients in SHUTTLE&#8217;s higher dose group achieved the endpoint, a 28.7% difference vs. placebo, while 54.1% of patients in the lower dose group achieved the endpoint, a 30.4% difference vs. placebo.</li>
<li>For vIGA-AD 0/1, 26.1% of SHUTTLE patients in the higher dose group achieved the endpoint, a 13.8% difference vs. placebo. In the lower dose group: 25.8% vs. 13.5%.</li>
<li>For rIGA 0/1, 23.3% of SHUTTLE patients in the higher dose group achieved the endpoint, an 11.5% difference vs. placebo and 22.7% vs. 10.9% in the lower dose group.</li>
</ul>
</li>
</ul>
The VOYAGER study demonstrated that rocatinlimab does not interfere with responses to tetanus and meningococcal vaccinations.
William Blair writes rocatinlimab results validate the OX40 mechanism, likely supporting a moderate commercial opportunity for patients after Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and Regeneron Pharmaceutical Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent and Eli Lilly &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Ebglyss.
Price Action: AMGN stock is up 2.4% at $332.90 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44223752/india-based-sun-pharma-to-buy-us-cancer-firm-checkpoint-therapeutics-for-410-per-share" target="_blank" rel="noreferrer noopener">India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details</a></li>
</ul>
Photo: Shutterstock

AMGN

REGN

Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study

On Friday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) released new results from Ebglyss&#8217;s (lebrikizumab-lbkz) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">long-term study, ADjoin</a>.
New data shows Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44189249/lillys-ebglyss-lebrikizumab-lbkz-single-monthly-maintenance-injection-achieved-completely-clear-sk" rel="noreferrer noopener">at three years</a>.
Ebglyss was approved in the U.S. in&nbsp;September 2024&nbsp;as a first-line monotherapy biologic treatment option following <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40884197/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss" rel="noreferrer noopener">topical prescription therapies</a>.
Of the patients who responded to treatment at Week 16 and received once-monthly maintenance dosing, 50% achieved complete skin clearance (EASI 100 or IGA 0) at three years.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44175948/alzheimers-drugs-from-eli-lilly-and-biogen-still-deemed-too-costly-for-nhs-funding" rel="noreferrer noopener">Alzheimer&#8217;s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding</a>
Additionally, 87% achieved or maintained almost-clear skin (EASI 90) at three years.
Over 83% of Week 16 responders taking EBGLYSS did not require concomitant therapies such as topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) for the duration of the ADjoin study.
Additional study assessments conducted in patients with skin of color (<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4376941-1&amp;h=4271923845&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2024-03-10-More-than-two-thirds-of-people-with-atopic-dermatitis-and-skin-of-color-experienced-skin-improvement-in-a-first-of-its-kind-lebrikizumab-study&amp;a=ADmirable" rel="noreferrer noopener">ADmirable</a>) and patients who were previously treated with Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) / Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (dupilumab) (<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4376941-1&amp;h=695585820&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2024-10-25-Lillys-EBGLYSS-TM-lebrikizumab-lbkz-demonstrated-meaningful-improvement-in-skin-clearance-and-itch-relief-in-the-majority-of-patients-with-moderate-to-severe-atopic-dermatitis-who-discontinued-dupilumab&amp;a=ADapt" rel="noreferrer noopener">ADapt</a>) showed improvements in itch, skin pain (discomfort and soreness), and itch interference with sleep.
<ul>
<li>In ADmirable, nearly 60% of patients achieved significant improvement in itch and skin pain at Week 16 (58% and 59%, respectively). Over 30% of patients saw a reduction in sleep loss due to itch at Week 16.</li>
<li>In ADapt, 75% achieved significant improvement in skin pain, and 62% achieved significant improvement in itch at Week 24. 42% of patients saw a reduction in sleep loss <a href="https://www.benzinga.com/general/biotech/24/10/41553086/eli-lillys-newly-fda-approved-eczema-drug-improves-skin-and-itch-in-patients-previously-treated-w" target="_blank" rel="noreferrer noopener">due to itch at Week 24</a>.</li>
</ul>
Price Action: LLY stock is down 0.36% at $909.50 during the premarket session at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/03/44189581/saas-company-liveramp-lays-off-5-of-full-time-workforce-amid-strategic-restructuring" target="_blank" rel="noreferrer noopener">SaaS Company LiveRamp Lays Off 5% Of Full-Time Workforce Amid Strategic Restructuring</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients

On Monday, Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) released interim Phase 1 results from its first-in-human <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44071970/apogee-therapeutics-announces-positive-interim-phase-1-results-from-the-apg990-healthy-volunteer-t" rel="noreferrer noopener">trial of APG990</a>.
APG990 interim Phase 1 pharmacokinetic (PK) data showed a half-life of approximately 60 days across doses tested.
Key data from the 40-healthy subject trial showed:
<ul>
<li>APG990 demonstrated a potential best-in-class PK profile, including a half-life of approximately 60 days, supporting the potential for every three- and six-month maintenance dosing. The PK profile supports the potential for a single 2 mL co-formulated injection of APG279 (APG777 + APG990) administered every three and six months.</li>
<li>APG990 was well tolerated across all five cohorts, with doses up to 1,200mg. The most common (≥10%) treatment-emergent adverse events (TEAEs) were headache.53% of participants observed at least one TEAE.</li>
<li>There were no Grade 3 TEAEs related to the study drug or severe adverse events. No adverse events led to study discontinuation. There have been no cases of pyrexia or chills.</li>
</ul>
In addition, preclinical studies of the combination of APG777 and APG990 showed potential for enhanced pharmacologic responses relative to individual agents and exhibited no safety findings at any dose level, including the highest dose tested of 150 mg/kg per agent in a 3-month combination toxicology study.
The company plans to submit an Investigational New Drug application or foreign equivalent for APG279.
Following clearance, the company plans to initiate a Phase 1b clinical trial in moderate-to-severe atopic dermatitis (AD) of APG279 against Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) / Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent (dupilumab) in 2025, with data expected in the second half of 2026.
The company says cash, cash equivalents, and marketable securities were $731.1 million as of December 31, 2024. Based on current operating plans, Apogee expects its existing cash, cash equivalents, and marketable securities will enable the company to fund its operating expenses into the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44072186/apogee-therapeutics-provides-pipeline-progress-and-reports-full-year-2024-financial-results" rel="noreferrer noopener">first quarter of 2028</a>.
Price Action: APGE stock is up 7.14% at $33.68 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44072910/ast-spacemobile-teams-up-with-vodafone-for-satellite-broadband-service-across-europe" target="_blank" rel="noreferrer noopener">AST SpaceMobile Teams Up with Vodafone For Satellite Broadband Service Across Europe</a></li>
</ul>

APGE

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

On Thursday,&nbsp;Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) reported fourth-quarter 2024 sales of $88.31 million, compared to&nbsp;$291 million&nbsp;a year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $84.35 million</a>. The decrease was due to lower product sales under APA agreements.
The COVID-19 vaccine maker reported an earning loss of 51 cents per share, down from $1.44 a year ago, in line <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n44004179/novavax-reports-fourth-quarter-and-full-year-2024-financial-results-and-operational-highlights" rel="noreferrer noopener">with the Wall Street Estimate</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42323263/wegovy-maker-novo-nordisk-to-buy-novavaxs-czech-republic-manufacturing-facility-for-200-million" rel="noreferrer noopener">Wegovy Maker Novo Nordisk To Buy Novavax&#8217;s Czech Republic Manufacturing Facility For $200 Million</a>
&#8220;In 2024, we unveiled our new corporate growth strategy, shifting our focus from commercializing our COVID-19 vaccine to maximizing the value of our cutting-edge technology platform through pipeline expansion and partnerships for our development-stage vaccine candidates and our Matrix-M adjuvant,&#8221; said&nbsp;John C. Jacobs, President and Chief Executive Officer, Novavax. &#8220;As we look to 2025 and beyond, we believe we are well positioned to potentially create significant value for all stakeholders.&#8221;
Nuvaxovid sales reached $49.8 million, down from $251.5 million a year ago. The company ended 2024 with over&nbsp;$1 billion&nbsp;in cash and accounts receivables.
Novavax has transitioned the lead commercial responsibility of Nuvaxovid to Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) for select markets beginning with the 2025-<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38758287/some-breather-for-novavaxs-covid-19-vaccine-inks-multibillion-dollar-deal-with-sanofi-and-erases-" rel="noreferrer noopener">2026 vaccination season</a>.
Since Novavax is reliant on Sanofi&#8217;s sales forecasts for certain revenue components, these will not be included in the 2025 Revenue Framework at this time.
Novavax expects to achieve adjusted licensing, royalties, and other revenue of between&nbsp;$300 million&nbsp;and $350 million in 2025. Novavax is eligible to receive royalties in the high teens to low twenties percent on Sanofi sales.
<h2 class="wp-block-heading">Novavax Stock Prediction For 2025</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Novavax have an average 1-year price target of $19.0, representing an expected upside of 141.41%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Novavax, while 1 analysts have bullish ratings. The street high price target from HC Wainwright &amp; Co. is $19.0, while the street low from HC Wainwright &amp; Co. is $19.0.
Price Action: NVAX stock is up 10.4% at $8.08 at the last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/44010386/why-is-ad-giant-wpp-stock-falling-today" target="_blank" rel="noreferrer noopener">Why Is Ad Giant WPP Stock Falling Today?</a></li>
</ul>

Earnings

Guidance

Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value

<a href="https://www.cdc.gov/bird-flu/spotlights/h5n1-response-02262025.html#:~:text=As%20of%20February%2024%2C%20CDC,backyard%20poultry%20flock%20(Wyoming).">https://www.cdc.gov/bird-flu/spotlights/h5n1-response-02262025.html#:~:text=As%20of%20February%2024%2C%20CDC,backyard%20poultry%20flock%20(Wyoming).</a>
&nbsp;
<h2>Situation Update</h2>
February 26, 2025 &ndash; CDC continues to respond to the public health challenge posed by a multistate outbreak of avian influenza A(H5N1) virus, or &quot;H5N1 bird flu,&quot; in dairy cows, poultry, and other animals in the United States. CDC is working in collaboration with the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), Administration for Strategic Preparedness and Response (ASPR), state public health and animal health officials, and other partners using a <a href="https://www.cdc.gov/one-health/about/index.html">One Health approach</a>.

CVAC

CDC A(H5N1) Bird Flu Response Update February 26, 2025; Confirmed 3 Human Cases Of H5 Bird Flu In People Who Became Ill In 2025 - Website

Macro Economic Events

Econ #s

Economics

U.S. Agriculture Secretary Brooke Rollins Says USDA Will Invest Up To $1B In Strategy To Curb Avian Flu; USDA Is Not Yet Authorizing Use Of Bird Flu Vaccines For Chickens

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma&nbsp;
<ul>
<li>Approval offers access to new treatment options for newly diagnosed MM patients</li>
<li>Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with VRd significantly improved progression-free survival, compared to VRd alone in transplant-ineligible newly diagnosed multiple myeloma</li>
</ul>

Sanofi Gains Japanese Approval For Sarclisa In Newly Diagnosed Multiple Myeloma Patients

On Saturday, Teva Pharmaceuticals Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV&#8217;574/SAR447189) for moderate-to-severe ulcerative colitis (UC) and Crohn&#8217;s disease (CD), the two most common forms of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43900182/teva-and-sanofi-present-new-positive-phase-2b-study-results-at-ecco-2025-reinforcing-best-in-class" rel="noreferrer noopener">inflammatory bowel disease (IBD)</a>.
These results were shared at the Congress of the European Crohn&#8217;s and Colitis Organisation.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43601535/axsome-therapeutics-resolves-generic-patent-litigation-with-teva-over-depression-drug-analyst-maintains-axsome-as-top-pick-for-2025" rel="noreferrer noopener">Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As &#8216;Top Pick For 2025&#8217;</a>
Ulcerative colitis
<ul>
<li>In the UC cohort of the RELIEVE UCCD study, 36% (450 mg dose) and 48% (900 mg dose) of patients treated with duvakitug achieved the primary endpoint of clinical remission (mMS) at week 14 compared to 20% treated with placebo.</li>
<li>Placebo-adjusted rates were 16% (450 mg) and 27% (900 mg) (p=0.050 and 0.003, respectively).
<ul>
<li>Higher clinical remission rates were observed for both doses of duvakitug versus placebo in both advanced therapy (AT)-experienced and AT-naïve subgroups of patients.AT-experienced: 29% (450 mg) and 36% (900 mg), with placebo-adjusted rates of 22% (450 mg) and 29% (900 mg).</li>
<li>AT-naïve: 39% (450 mg) and 53% (900 mg), with placebo-adjusted rates of 12% (450 mg) and 26% (900 mg).1-3</li>
</ul>
</li>
</ul>
Crohn&#8217;s disease
<ul>
<li>In the CD cohort of the RELIEVE UCCD study, 26% (450 mg) and 48% (900 mg) of patients with CD treated with duvakitug achieved the primary endpoint of endoscopic response (SES-CD) compared to 13% on placebo.</li>
<li>Placebo-adjusted rates were 13% (450 mg) and 35% (900 mg) at week 14 (p=0.058 and &lt;0.001, respectively).
<ul>
<li>Higher endoscopic response rates were observed for both doses of duvakitug versus placebo in both AT-experienced and -naïve subgroups of patients.AT-experienced: 11% (450 mg) and 48% (900 mg), with placebo-adjusted rates of 7% (450 mg) and 44% (900 mg).</li>
<li>AT-naïve: 47% (450 mg) and 47% (900 mg), with placebo-adjusted rates of 25% (450 mg) and 25% (900 mg).</li>
</ul>
</li>
</ul>
The company expects to start the Phase 3 program in the second half of 2025.
Price Action: TEVA stock is down 0.18% at $16.70, and SNY stock is down 0.48% at $54.20 during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43901425/apple-bows-out-of-uks-cloud-encryption-amid-governments-backdoor-demands" target="_blank" rel="noreferrer noopener">Apple Bows Out of UK&#8217;s Cloud Encryption Amid Government&#8217;s &#8216;Backdoor&#8217; Demands</a></li>
</ul>
Photo by Ralf Liebhold via Shutterstock

TEVA

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease

<ul>
<li>New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses</li>
<li>New endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvement</li>
<li>Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025</li>
</ul>

Small Business

Reported Saturday, Teva and Sanofi Presented Phase 2b Data At ECCO 2025, Highlighting Duvakitug's Promise For Ulcerative Colitis And Crohn's Disease

Sanofi And CD&R Finalize Share Purchase Agreement For 50% Stake In Opella

On Friday, the FDA approved Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Merilog as a biosimilar to Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Novolog (insulin aspart) for improving glycemic control in adults and pediatric patients with diabetes mellitus.
Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43692253/sanofi-johnson-johnson-partnered-vaccine-against-bacterial-sepsis-flunks-late-stage-study" rel="noreferrer noopener">Sanofi/Johnson &amp; Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study</a>
As a rapid-acting insulin, Merilog helps lower mealtime blood sugar spikes and improve blood sugar control in people with diabetes. The <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-rapid-acting-insulin-biosimilar-product-treatment-diabetes" rel="noreferrer noopener">approval </a>is for a 3 milliliter (mL) single-patient-use prefilled pen and a 10 milliliter (mL) multiple-dose vial.
Merilog is the third insulin biosimilar product the FDA has approved, joining the two long-acting insulin biosimilar products the agency approved in 2021.
A biosimilar is a &#8220;biological product that is highly similar to, and has no clinically meaningful differences from, a biological product already approved by the FDA (also called the reference product).&#8221; The FDA has approved 65 biosimilar products to date.
Like Novolog, Merilog should be administered within five to ten minutes before the start of a meal. Merilog is administered subcutaneously (under the skin) by injection into the stomach, buttocks, thighs, or upper arms. Dosing of Merilog should be individualized and adjusted based on the patient&#8217;s needs.
Merilog may cause serious side effects, including hypoglycemia (low blood sugar), severe allergic reactions, and hypokalemia (low potassium in blood). Other common side effects may include injection site reactions, itching, rash, lipodystrophy (skin thickening or pitting at the injection site), weight gain, and swelling of hands and feet.
In 2023, Sanofi jumped the bandwagon with the other two insulin U.S. giants to&nbsp;lower the price of its best-selling insulin product, Lantus <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31394427/three-is-company-sanofi-follows-lilly-novo-nordisk-slashes-insulin-product-price-by-78" rel="noreferrer noopener">(insulin glargine), by 78%</a>.
Sanofi said it would cap a&nbsp;Lantus patient&#8217;s monthly out-of-pocket cost at $35 for all patients with commercial insurance.&nbsp;
Also, in 2023, Sanofi acquired&nbsp;Provention Bio for $25.00 per share in cash, representing an equity value of <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31318877/provention-bios-2-9b-acquisition-a-strategic-fit-for-sanofi" rel="noreferrer noopener">approximately $2.9 billion</a>.
The transaction adds a type 1 diabetes therapy to Sanofi&#8217;s core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile.&nbsp;
In November, Doctors Without Borders/Médecins Sans Frontières highlighted that&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Novo Nordisk, and Sanofi, which dominate the global insulin market, have the power to set high&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41940958/humanitarian-organization-criticizes-eli-lilly-novo-nordisk-and-sanofi-of-having-double-standards-for-high-insulin-price" rel="noreferrer noopener">prices that restrict access</a>.
According to MSF, data published in&nbsp;JAMA Network Open&nbsp;shows that insulin pens could be produced for as little as $0.94 per unit and remain profitable, yet current prices far exceed this figure.
Price Action: SNY stock is down 0.59% at $54.18 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43744606/analyst-cautiously-optimistic-on-dexcom-as-competitive-pressures-loom" target="_blank" rel="noreferrer noopener">Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom</a></li>
</ul>
Image by HJBC via Shutterstock

FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes

<ul>
<li>If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025</li>
<li>Priority Review granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placebo</li>
<li>BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions</li>
</ul>

Regeneron And Sanofi Announce FDA Priority Review For Dupixent In Bullous Pemphigoid, With Approval Decision Expected By June 2025

Soros Fund Management Cuts Share Stake In Sanofi By 50% To 200,000 Sponsored ADRs

U.S. FDA Approves Sanofi-Aventis U.S' Merilog & Merilog Solostar, Biosimilars To Novo Nordisk's Novolog

Sanofi's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NYSE">SNY</a>) short percent of float has fallen 8.33% since its last report. The company recently reported that it has 4.88 million shares sold short, which is 0.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.61 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sanofi Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739554222_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sanofi has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Sanofi's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sanofi's peer group average for short interest as a percentage of float is 4.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

How Is The Market Feeling About Sanofi?

<a href="https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm" title="https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm">https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm</a>

U.S. CDC Report: Evidence Found Of Recent Bird Flu Infections Among 3 Cattle Veterinarians

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) have discontinued the E.mbrace phase 3 study evaluating a vaccine candidate for extraintestinal pathogenic&nbsp;E. coli.
The E.mbrace <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-02-13-06-00-00-3025576" rel="noreferrer noopener">study</a> is a randomized, double-blind, placebo-controlled, multicenter, interventional phase 3 study evaluating the efficacy, safety, and immunogenicity of a single dose of the vaccine candidate compared to a placebo in the prevention of IED, which includes sepsis and bacteremia (blood infections).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43142442/sanofi-genzyme-facility-fda-quality-lapses" rel="noreferrer noopener">Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses</a>
An independent data monitoring committee (IDMC) conducted a scheduled review of the E.mbrace phase 3 study.
The companies determined that the vaccine candidate was not sufficiently effective at preventing invasive&nbsp;E. coli disease (IED) compared to placebo.
No safety signals related to the vaccine candidate were identified, and throughout the study, investigators ensured that participants who developed IED received prompt treatment and care.
In October 2023, Sanofi entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson &amp; Johnson company, to develop and commercialize the vaccine candidate.
Under the terms of the agreement, both parties agreed to co-fund current and future research and development costs. Sanofi paid $250 million in upfront and development milestones to be followed by commercial milestones.
The study was initiated in June 2021 enrolling adults aged 60 years or older in stable health with a history of urinary tract infection in the past two years.
As a result of the discontinuation, Sanofi has recorded an impairment charge before tax of $250 million in the Q4 2024 IFRS results. This adjustment negatively impacts the full-year IFRS EPS reported in the Q4 2024 results press release on January 30, 2025, by 15 cents, from 4.59 euros previously to 4.44 euros now.
However, there is no impact on the business net income/EPS, which remain unchanged, respectively, at 8.91 billion euros/ 7.12 euros (non-IFRS).
Price Action: As of Thursday, SNY stock was up 0.18% at $54.66 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43676723/third-harmonic-bio-initiates-strategic-review-lays-off-50-staff-citing-competitive-landscape" target="_blank" rel="noreferrer noopener">Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape</a></li>
</ul>
Image by HJBC via Shutterstock

Contracts

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study

Press Releases

Sanofi ships U.S. influenza vaccines for the 2024/25 season

Ontario Ministry of Health Announces a Universal Public Program with Beyfortus® this RSV Season

Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza

Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities

Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA

Opinion

Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies

FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals

Beyfortus® immunization to protect infants from RSV has begun

Penny Stocks

Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

ANVS

AVTE

CTRX

DVAX

GTHX

HALO

HPTX

HZNP

ONCY

TARS

TSX:ONC

ZNTL

ZSPH

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Argus Research

Morgan Stanley

Screenshot 2025-03-12 at 4.47.01 PM

BIIB

ELDN

TNXP

Tonix&#39;s TNX-1500 Shows Promise In Preventing Organ Transplant Rejections Of Either Human Or Pig Organs; Autoimmune Diseases Also A Target

Redington 2_29

BDRX

PowerShares Dynamic Financial Sector Portfolio

Comments

Sanofi

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL